NUTRITION 21, LLC ANNOUNCES THE PRESENTATION OF A CLINICAL EVALUATION OF THE DURATION OF THE EFFECT OF NITROSIGINE®

NUTRITION 21, LLC ANNOUNCES THE PRESENTATION OF A CLINICAL EVALUATION OF THE DURATION OF THE EFFECT OF NITROSIGINE® AT THE RENOWNED EXPERIMENTAL BIOLOGY 2016 ANNUAL MEETING

PURCHASE, NEW YORK – APRIL 6, 2016 – Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of new clinical study results supporting the bioavailability of Nitrosigine® bonded arginine silicate (ASI), titled, “A Pharmacokinetic Evaluation of the Duration of Effect of Inositol-Stabilized Arginine Silicate and Arginine Hydrochloride in Healthy Adult Males.” The study was presented on April 3rd, 2016 to scientists and other professionals at the acclaimed Experimental Biology 2016 annual meeting and the abstract will be published in the Federation of American Societies for Experimental Biology Journal (FASEB).

Read the full press release here – Nitrosigine® Supplementation Significantly Increases Arginine Levels

To find out more about Nitrosigine, visit http://www.Nitrosigine.com